Proof of Concept Study to Assess Activity and Safety of SMT C1100 (Ezutromid) in Boys With Duchenne Muscular Dystrophy (DMD)

NCT02858362 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

43

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated due to lack of efficacy in Cohorts 1 and 2.

Conditions

Duchenne Muscular Dystrophy

Interventions

DRUG: Ezutromid

Sponsor

Summit Therapeutics